Isthmus Partners LLC Increases Position in HCA Healthcare, Inc. (NYSE:HCA)

Isthmus Partners LLC lifted its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 0.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,973 shares of the company’s stock after purchasing an additional 35 shares during the period. HCA Healthcare comprises about 1.7% of Isthmus Partners LLC’s portfolio, making the stock its 19th largest holding. Isthmus Partners LLC’s holdings in HCA Healthcare were worth $14,621,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. MFA Wealth Advisors LLC purchased a new stake in HCA Healthcare during the 2nd quarter worth approximately $27,000. Unique Wealth Strategies LLC acquired a new position in shares of HCA Healthcare during the 2nd quarter worth approximately $28,000. Bangor Savings Bank boosted its holdings in shares of HCA Healthcare by 112.5% during the 2nd quarter. Bangor Savings Bank now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. GPS Wealth Strategies Group LLC boosted its holdings in shares of HCA Healthcare by 284.0% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after purchasing an additional 71 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in shares of HCA Healthcare during the 3rd quarter worth approximately $41,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $325.47 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. The company has a market cap of $82.44 billion, a P/E ratio of 14.61, a PEG ratio of 1.25 and a beta of 1.68. HCA Healthcare, Inc. has a 52 week low of $245.84 and a 52 week high of $417.14. The company has a 50-day moving average price of $373.42 and a 200 day moving average price of $358.28.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be given a $0.66 dividend. The ex-dividend date is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.81%. HCA Healthcare’s payout ratio is currently 11.85%.

Insider Activity at HCA Healthcare

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now directly owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael S. Cuffe sold 8,358 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the transaction, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. This trade represents a 21.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,155 shares of company stock worth $5,608,990 over the last 90 days. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on HCA. Oppenheimer upped their price objective on HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a report on Monday, October 28th. Barclays decreased their price target on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Raymond James lowered HCA Healthcare from an “outperform” rating to a “market perform” rating in a research report on Friday, November 22nd. TD Cowen dropped their target price on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a report on Monday, October 28th. Finally, Truist Financial increased their target price on HCA Healthcare from $390.00 to $430.00 and gave the company a “buy” rating in a report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, HCA Healthcare currently has an average rating of “Moderate Buy” and a consensus target price of $380.29.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.